GLD Acquires Seelos Therapeutics’ Assets, Strengthening GLD’s Growing Life Sciences Portfolio
GLD Announces Successful Closing of Seelos Assets; Includes Ketamine and Trehalose Programs Advancing into Phase 3 Clinical Trials
For media inquiries, contact:
info@gldlp.com
News & Announcements
Join our mailing list for the latest news and announcements.